Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

@article{Poplin2009PhaseIR,
  title={Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.},
  author={Elizabeth A. Poplin and Yang Feng and Jordan Berlin and Mace L. Rothenberg and Howard S. Hochster and Edith Mitchell and Steven Alberts and Peter J. O'dwyer and Daniel Haller and Paul Catalano and David Cella and Al Bowen Benson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 23},
  pages={3778-85}
}
PURPOSE Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m(2)/30 minutes versus GEM FDR 1,500 mg/m(2)/150 minutes or GEM 1,000 mg/m(2)/100 minutes/day 1 plus oxaliplatin 100 mg/m(2)/day 2 every 14 days (GEMOX). METHODS This trial included patients with metastatic or locally… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 173 extracted citations

Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.

Hematology/oncology clinics of North America • 2015
View 12 Excerpts
Highly Influenced

Current and emerging therapies for the treatment of pancreatic cancer

OncoTargets and therapy • 2010
View 6 Excerpts
Highly Influenced

A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology • 2012
View 4 Excerpts
Highly Influenced

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 4 Excerpts
Highly Influenced

Palliative chemotherapy for pancreatic malignancies.

The Surgical clinics of North America • 2010
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer

MM Javle, T Okazaki, DB Evans
J Clin Oncol 26:213s, 2008 • 2008

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine

E Giovannetti, M Del Tacca, V Mey
Cancer Res • 2006

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…